SCHEMBL2482471

SCHEMBL2482471

NC(=O)c1cnc(Cl)cc1NCc1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 3/20 0.60
AKT1 P31749 1/20 0.60
CD38 P28907 1/20 0.56
JAK3 P52333 5/20 0.53
JAK2 O60674 3/20 0.53
JAK1 P23458 3/20 0.53
IRAK4 Q9NWZ3 2/20 0.53
TYK2 P29597 2/20 0.53
VNN1 O95497 2/20 0.53
HDAC3 O15379 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
STAT6 P42226 1/20 0.48
CSF1R P07333 1/20 0.47
BTK Q06187 1/20 0.47
MAPK8 P45983 1/20 0.47
AURKA O14965 2/20 0.47
EGFR P00533 1/20 0.45
IGF1R P08069 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12456033 0.89 RPS6KB1 (0.54) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL2480282 0.88 JAK3 (0.67) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL12330858 0.88 JAK3 (0.51) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL2694894 0.88 JAK3 (0.51) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL2476348 0.88 JAK3 (0.52) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL2475770 0.88 CDC7 (0.58) RPS6KB1AKT1JAK3JAK2JAK1
SCHEMBL2479562 0.88 RPS6KB1 (0.55) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL2483253 0.85 JAK3 (0.49) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL2484302 0.85 JAK3 (0.49) RPS6KB1AKT1CD38JAK3JAK2
SCHEMBL12206941 0.85 JAK3 (0.55) RPS6KB1AKT1CD38JAK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA RPS6KB1 3316/4885AKT1 2628/4885CD38 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.